Joseph Schwartz
Stock Analyst at Leerink Partners
(3.13)
# 1,154
Out of 4,876 analysts
138
Total ratings
31.3%
Success rate
16.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $100 → $115 | $101.74 | +13.03% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $7.38 | +62.60% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $12.74 | +119.78% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $15.13 | +164.38% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.38 | +3,584.21% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.08 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $4.81 | +149.48% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.80 | +185.71% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.22 | -18.03% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $3.82 | +57.07% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $49.55 | -3.13% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $17.44 | +3.21% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $11.50 | +73.91% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $39.78 | -14.53% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $54.10 | +140.30% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $17.23 | +828.61% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $173.17 | -5.87% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.30 | +669.23% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.28 | +2,478.13% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.63 | +39.05% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $37.13 | +190.87% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $29.99 | +30.04% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $0.83 | +380.42% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $13.06 | +129.71% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $29.83 | +67.62% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $55.22 | -45.67% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $14.23 | +293.53% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.69 | +146.05% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.16 | +455.56% | 2 | Sep 26, 2017 |
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $101.74
Upside: +13.03%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.38
Upside: +62.60%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $12.74
Upside: +119.78%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $15.13
Upside: +164.38%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.38
Upside: +3,584.21%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $4.81
Upside: +149.48%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.80
Upside: +185.71%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.22
Upside: -18.03%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.82
Upside: +57.07%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $49.55
Upside: -3.13%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $17.44
Upside: +3.21%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $11.50
Upside: +73.91%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $39.78
Upside: -14.53%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $54.10
Upside: +140.30%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $17.23
Upside: +828.61%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $173.17
Upside: -5.87%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.30
Upside: +669.23%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.28
Upside: +2,478.13%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.63
Upside: +39.05%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $37.13
Upside: +190.87%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $29.99
Upside: +30.04%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $0.83
Upside: +380.42%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $13.06
Upside: +129.71%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $29.83
Upside: +67.62%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $55.22
Upside: -45.67%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $14.23
Upside: +293.53%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $5.69
Upside: +146.05%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.16
Upside: +455.56%